高级别浆液性卵巢癌的初始减瘤手术：当前证据
Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence.
作者信息
Tsonis Orestis, Gkrozou Fani, Vlachos Konstantinos, Paschopoulos Minas, Mitsis Michail C, Zakynthinakis-Kyriakou Nikolaos, Boussios Stergios, Pappas-Gogos George
机构信息
Department of Obstetrics and Gynaecology, University Hospital of Ioannina, Ioannina, Greece.
Department of Obstetrics and Gynaecology, University Hospitals Birmingham, Birmingham, UK.
出版信息
Ann Transl Med. 2020 Dec;8(24):1707. doi: 10.21037/atm-20-1620.
Abstract
High-grade serous ovarian carcinoma (HGSOC) is a leading cause of mortality among women worldwide. Currently, there is no clear consensus over the regime these patients should receive. The main two options are upfront debulking surgery with adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The former approach is proposed to be accompanied by lower chemoresistance rates but could lead to severe surgical comorbidities and lower quality of life (QoL). Optimizing patient's selection for upfront debulking surgery might offer higher progression-free and overall survival rates. Further studies need to be conducted in order to elucidate the predictive factors, which are favorable for patients undergoing upfront debulking surgery in cases of high-grade serous ovarian cancer.
摘要
高级别浆液性卵巢癌（HGSOC）是全球女性死亡的主要原因之一。目前，对于这些患者应接受的治疗方案尚无明确共识。主要的两种选择是先行减瘤手术加辅助化疗，或新辅助化疗后行中间减瘤手术（IDS）。前一种方法被认为化疗耐药率较低，但可能导致严重的手术合并症和较低的生活质量（QoL）。优化先行减瘤手术患者的选择可能会提高无进展生存率和总生存率。需要进行进一步研究以阐明预测因素，这些因素有利于高级别浆液性卵巢癌患者接受先行减瘤手术。
相似文献
1
Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence.高级别浆液性卵巢癌的初始减瘤手术：当前证据
Ann Transl Med. 2020 Dec;8(24):1707. doi: 10.21037/atm-20-1620.
2
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.前瞻性手术与新辅助化疗后间隔减瘤手术治疗 IIIC 期和 IV 期卵巢癌患者的研究，SGOG SUNNY（SOC-2）试验方案。
J Gynecol Oncol. 2020 Sep;31(5):e86. doi: 10.3802/jgo.2020.31.e86.
3
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.新辅助化疗与中间型减瘤术治疗晚期输卵管-卵巢癌：来自 EORTC 55971 和 CHORUS 试验的个体患者数据的汇总分析。
Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6.
4
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗：生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
5
Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.Ⅲc-IV期高级别浆液性卵巢癌患者新辅助化疗后行间隔减瘤手术预后的潜在风险因素
J Obstet Gynaecol Res. 2018 Sep;44(9):1808-1816. doi: 10.1111/jog.13710. Epub 2018 Jul 18.
6
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.一项III期随机试验（日本临床肿瘤学组研究JCOG0602）中，新辅助化疗后，III/IV期卵巢癌、输卵管癌和腹膜癌的初始肿瘤细胞减灭术与间隔肿瘤细胞减灭术之间治疗侵袭性的比较
Eur J Cancer. 2016 Sep;64:22-31. doi: 10.1016/j.ejca.2016.05.017. Epub 2016 Jun 17.
7
The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.新辅助化疗联合中间型肿瘤细胞减灭术治疗铂敏感复发性卵巢癌中二次细胞减灭术的影响。
Gynecol Oncol. 2022 Jun;165(3):453-458. doi: 10.1016/j.ygyno.2022.03.024. Epub 2022 Apr 6.
8
Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.原发性晚期卵巢癌化疗 5 个周期以上后仍有残留病灶时延迟间隔肿瘤细胞减灭术的作用。一项国际多中心研究。
Gynecol Oncol. 2020 Nov;159(2):434-441. doi: 10.1016/j.ygyno.2020.08.028. Epub 2020 Sep 9.
9
Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.对于接受晚期减瘤手术的晚期高级别浆液性卵巢癌患者，化疗的长时间中断与预后不良相关。
Gynecol Oncol. 2020 Jul;158(1):54-58. doi: 10.1016/j.ygyno.2020.04.048. Epub 2020 Apr 25.
10
Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.优化卵巢癌治疗：新辅助化疗和间隔肿瘤缩小术与初始肿瘤细胞减灭术治疗可能无法实现理想切除的上皮性卵巢癌。
Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.
引用本文的文献
1
Prognostic Relevance of Clinical and Tumor Mutational Profile in High-Grade Serous Ovarian Cancer.高级别浆液性卵巢癌中临床和肿瘤突变特征的预后相关性
Int J Mol Sci. 2025 Aug 1;26(15):7416. doi: 10.3390/ijms26157416.
2
Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis.人网膜和肠系膜（卵巢癌转移的主要部位）细胞外基质成分的比较蛋白质组学分析。
bioRxiv. 2025 Jul 31:2025.07.28.667199. doi: 10.1101/2025.07.28.667199.
3
Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution.卵巢癌中的同源重组缺陷检测：一家意大利转诊机构的诊断经验
Pathologica. 2025 Jun;117(3):258-268. doi: 10.32074/1591-951X-1098.
4
Survival Dynamics in Advanced Ovarian Cancer: R2 Resection Versus No-Surgery Paths Explored.晚期卵巢癌的生存动态：探索R2切除与非手术路径
Cancer Control. 2024 Jan-Dec;31:10732748241285480. doi: 10.1177/10732748241285480.
5
Interplay between altered metabolism and DNA damage and repair in ovarian cancer.卵巢癌中代谢改变与 DNA 损伤和修复的相互作用。
Bioessays. 2024 Aug;46(8):e2300166. doi: 10.1002/bies.202300166. Epub 2024 Jun 14.
6
A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia.基于复发类型的复发性上皮性卵巢癌患者的生存分析：亚美尼亚多机构回顾性研究。
Curr Oncol. 2024 Mar 4;31(3):1323-1334. doi: 10.3390/curroncol31030100.
7
Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOC Cells.用查尔酮衍生物靶向卵巢癌：在高浆膜腔转移潜能卵巢癌细胞中诱导细胞毒性和细胞凋亡。
Molecules. 2023 Nov 25;28(23):7777. doi: 10.3390/molecules28237777.
8
Optimal First-Line Medico-Surgical Strategy in Ovarian Cancers: Are We There Yet?卵巢癌的最佳一线医疗-外科治疗策略：我们做到了吗？
Cancers (Basel). 2023 Jul 10;15(14):3556. doi: 10.3390/cancers15143556.
9
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.卵巢癌的同源重组缺陷内检测：一项多机构的意大利用户研究。
J Clin Pathol. 2024 Jun 19;77(7):478-485. doi: 10.1136/jcp-2023-208852.
10
F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study.F-DCFPyL PET/CT在晚期高级别上皮性卵巢癌中的应用：一项前瞻性初步研究。
Front Oncol. 2022 Oct 13;12:1025475. doi: 10.3389/fonc.2022.1025475. eCollection 2022.
本文引用的文献
1
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.基于女性种系多基因测序结果得出的乳腺癌和卵巢癌外显率估计值。
JCO Precis Oncol. 2017 Nov;1:1-12. doi: 10.1200/PO.16.00066.
2
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较
Cochrane Database Syst Rev. 2021 Feb 5;2(2):CD005343. doi: 10.1002/14651858.CD005343.pub5.
3
Endometriosis in adolescence: Early manifestation of the traditional disease or a unique variant?青春期子宫内膜异位症：传统疾病的早期表现还是独特变异？
Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:238-243. doi: 10.1016/j.ejogrb.2020.01.045. Epub 2020 Feb 7.
4
Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.未接受间隔肿瘤细胞减灭术的新辅助化疗卵巢癌患者的特征和生存情况。
J Gynecol Oncol. 2020 Jan;31(1):e17. doi: 10.3802/jgo.2020.31.e17.
5
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.尼拉帕利治疗卵巢癌：一种新的合成致死治疗方法。
Invest New Drugs. 2020 Feb;38(1):181-193. doi: 10.1007/s10637-019-00867-4. Epub 2019 Oct 24.
6
Kinase Inhibitors and Ovarian Cancer.激酶抑制剂与卵巢癌
Cancers (Basel). 2019 Sep 12;11(9):1357. doi: 10.3390/cancers11091357.
7
Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.新辅助肿瘤细胞减灭术与间隔性肿瘤细胞减灭术治疗腹膜假黏液瘤的疗效比较：一项回顾性队列研究
J Surg Oncol. 2019 Dec;120(7):1208-1219. doi: 10.1002/jso.25703. Epub 2019 Sep 17.
8
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).信任：晚期卵巢癌激进 upfront 外科治疗试验（ENGOT ov33/AGO-OVAR OP7）。
Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331. doi: 10.1136/ijgc-2019-000682. Epub 2019 Aug 15.
9
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.聚（ADP-核糖）聚合酶（PARP）抑制剂联合策略治疗卵巢癌：文献综述
Diagnostics (Basel). 2019 Aug 1;9(3):87. doi: 10.3390/diagnostics9030087.
10
Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?新辅助化疗后晚期卵巢癌患者的治疗策略：间隔减瘤术还是辅助化疗？
J Gynecol Oncol. 2019 Sep;30(5):e81. doi: 10.3802/jgo.2019.30.e81.
Zotero 插件